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transplants.2 Furthermore, this phenomenon of donor
microchimerism was present in some recipients who were
weaned from immunosuppression prospectively.
Subsequently, this phenomenon also occurred in recipi-
ents of other organs including hearts3 and lungs,4 and
donor microchimerism was found to be associated with a
lower incidence of chronic rejection in lung4 and in com-
bined kidney and pancreas5 transplant recipients. To aug-
ment donor cell microchimerism with the aim to enhance
long-term allograft survival, to attenuate the incidence of
acute and chronic rejection, and to reduce the need for
maintenance immunosuppression, we initiated a prospec-
tive trial combining the infusion of unmodified donor
bone marrow with heart transplantation. Reported herein
are the intermediate-term results of this trial.
Patients and methods
The Institutional Review Board of the University of
Pittsburgh approved this study on July 14, 1993, and informed
We previously reported that donor cells of bone mar-row lineages were widely distributed at a low level in
organs of long-surviving recipients of liver1 and kidney
Background: Donor chimerism (the presence of donor cells of bone marrow
origin) is present for years after transplantation in recipients of solid organs.
In lung recipients, chimerism is associated with a lower incidence of chron-
ic rejection. To augment donor chimerism with the aim to enhance graft
acceptance and to reduce immunosuppression, we initiated a trial combining
infusion of donor bone marrow with heart transplantation. Reported herein
are the intermediate-term results of this ongoing trial. 
Methods: Between September 1993 and August 1998, 28 patients received
concurrent heart transplantation and infusion of donor bone marrow at 3.0 ×
108 cells/kg (study group). Twenty-four contemporaneous heart recipients
who did not receive bone marrow served as controls. All patients received an
immunosuppressive regimen consisting of tacrolimus and steroids. 
Results: Patient survival was similar between the study and control groups
(86% and 87% at 3 years, respectively). However, the proportion of patients
free from grade 3A rejection was higher in the study group (64% at 6
months) than in the control group (40%; P = .03). The prevalence of coro-
nary artery disease was similar between the two groups (freedom from dis-
ease at 3 years was 78% in study patients and 69% in controls). Similar pro-
portions of study (18%) and control (15%) patients exhibited in vitro
evidence of donor-specific hyporesponsiveness. 
Conclusions: The infusion of donor bone marrow reduces the rate of acute
rejection in heart recipients. Donor bone marrow may play an important role
in strategies aiming to enhance the graft acceptance. (J Thorac Cardiovasc
Surg 2000;119:673-81)
Si M. Pham, MDa,c
Abdul S. Rao, MD, DPhila,b,c
Adriana Zeevi, PhDa,b,c
Robert L. Kormos, MDa
Kenneth R. McCurry, MDa
Brack G. Hattler, MD, PhDa
John J. Fung, MD, PhDa,c
Thomas E. Starzl, MD, PhDa,c
Bartley P. Griffith, MDa
From the Departments of Surgerya and Pathologyb and the Thomas E.
Starzl Transplant Institute,c University of Pittsburgh, Pittsburgh, Pa.
Supported in part by the American College of Surgeons Faculty Fellow-
ship, The Thoracic Surgery Research Foundation, American Heart
Association grants to Si M. Pham, and National Institutes of
Health grant AI40329 to John J. Fung and Abdul S. Rao.
Read at the Seventy-ninth Annual Meeting of The American Associ-
ation for Thoracic Surgery, New Orleans, La, April 18-21, 1999.
Received for publication May 13, 1999; revisions requested July 7,
1999; revisions received Nov 23, 1999; accepted for publication
Nov 24, 1999.
Address for reprints: Si M. Pham, MD, Jackson Memorial Hospital,
Highland Professional Bldg, 1801 NW 9th Ave, 5th Floor, Miami,
FL 33136 (E-mail: spham@med.miami.edu).
Copyright © 2000 by The American Association for Thoracic Surgery.
0022-5223/2000 $12.00 + 0 12/6/104704
doi:10.1067/mtc.2000.104704
673
A CLINICAL TRIAL COMBINING DONOR BONE MARROW INFUSION AND HEART TRANSPLANTATION:
INTERMEDIATE-TERM RESULTS
CARDIOTHORACIC TRANSPLANTATION
consent forms were obtained from all patients. Between
September 1993 and August 1998, 28 patients received com-
bined infusion of donor bone marrow and heart transplanta-
tion (study group). In addition, unavailability of consent to
retrieve bone marrow resulted in the accrual of 24 contempo-
raneous heart transplant recipients as controls. The demo-
graphic information is depicted in Table I. Except for the
longer donor ischemic time in the control group, the two
groups are comparable in age, sex, major histocompatibility
complex (MHC) mismatch, and the duration of follow-up. All
patients underwent primary orthotopic heart transplantation,
without cytoablative or cytoreductive conditioning.
Furthermore, none of these patients had a positive lymphocy-
totoxic crossmatch. 
Bone marrow preparation. Donor bone marrow cells
were isolated from thoracolumbar vertebrae as described.6
They were infused (3-6 × 108 cells/kg body weight) into the
patient within 2 hours after preparation and between 6 and 10
hours after revascularization of the heart. 
Immunosuppression. The immunosuppression regimen
consisted of tacrolimus (FK506, Prograf; Fujisawa USA,
Deerfield, Ill) and steroids, as previously described.7 Two
months after transplantation, if there was no evidence of sig-
nificant rejection by endomyocardial biopsy, systematic
prospective steroid reduction (by 2.5- to 5-mg decrements)
was initiated in all patients. Azathioprine (Imuran; Burroughs
Wellcome, Research Triangle Park, NC; 2 mg/kg per day) or
mycophenolate mofetil (CellCept; Roche Laboratories,
Nutley, NJ; 2 g per day) was added in case of recurrent rejec-
tion or renal dysfunction (serum creatinine level > 2.0 mg/dL)
necessitating a reduction of the tacrolimus dose. 
Monitoring and treatment of rejection. Surveillance for
rejection consisted of weekly endomyocardial biopsies dur-
ing the first month, monthly for the next 3 months, and every
3 months thereafter during the first year after transplantation.
Subsequently, biopsies were performed semiannually. In
addition, endomyocardial biopsies were performed whenever
clinically indicated. The severity of acute rejection was grad-
ed according to the criteria of the International Society for
Heart and Lung Transplantation.8 Rejection was treated ini-
tially with steroid boluses (1 g methylprednisolone per day
for 3 days), whereas OKT3 was reserved for steroid-resistant
rejection.
Detection of chimerism. All recipients were evaluated for
the presence of donor chimerism in their peripheral blood by
flow cytometry7 and polymerase chain reaction (PCR).7,9
Blood samples (20 mL) from the patients were obtained on
days 0 (time of transplantation), 15, 30, and 60 and every
other month thereafter. For cytometric analysis, values of cir-
culating donor cells of less than 0.5% were considered below
the level of sensitivity. In this latter group of patients, quali-
tative PCR was subsequently used to serially evaluate the
presence of donor cell chimerism. In some female recipients
who had received a male heart, donor (male) DNA in a test
sample was quantified by means of the nested PCR method.9
Immune monitoring. The recipient’s immune status was
assessed before and serially after transplantation by mixed
lymphocyte reaction, mitogen response assay (proliferative
responses of the recipient’s peripheral blood leukocytes to
concanavalin A, and phytohemagglutinin), and lymphocyte
growth assay (propagation of lymphocytes from endomyo-
cardial biopsy specimens), as previously reported.10,11
Statistical analysis. Continuous variables were expressed
as mean ± standard deviation (SD) and compared by means
of the t test or Mann-Whitney U test when appropriate.
Differences in proportions were compared by means of the χ2
or Fisher exact tests. Survival, freedom from acute rejection,
and freedom from coronary artery disease were estimated by
the Kaplan-Meier method and compared by means of the log-
rank test. The stepwise Cox proportional hazard method was
used for multivariate analyses of influences of demographic
and other risk factors on outcomes. For the analysis of the
levels of chimerism over time, we used the SAS PROC
MIXED analysis of variance software (Littell RC, Milliken
GA, Stroup WW, Wolfinger RD: SAS system for mixed mod-
els, SAS Institute Inc, Cary, NC, 1996). This software
enables us to analyze longitudinal data with missing values.
Results
Clinical course and patient survival. The infusion
of donor bone marrow was well tolerated. None of the
recipients had graft-versus-host disease or complica-
tions related to the infusion of donor bone marrow. The
3-year patient survivals were 87% and 86% in the con-
trol and study groups, respectively (P = .9, Fig 1). Four
study patients died during the follow-up period of per-
forated gastric ulcer, pulmonary embolism, post-trans-
plantation lymphoproliferative disease, and multiple
organ system failure from noncompliance with the
treatment protocol. In the control group, 3 died, 2 of
infection (1 viral and 1 bacterial) and 1 of post-trans-
plantation lymphoproliferative disease. 
Immunosuppression profiles. At last follow-up
contact or at the time of death, the level of tacrolimus,
the dose of prednisone, the number of patients receiv-
ing prednisone, and the number of patients requiring a
third immunosuppressant (either azathioprine or
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Table I. Demographics of heart recipients
Variables BM + heart Heart alone P value
n 28 24
Recipient’s age (y) 49.8 ± 11.1 53.6 ± 8.2 .3
Donor’s age (y) 28.2 ± 11.0 31.3 ± 11.9 .3
Sex (male/female) 26:2 20:4 .4
Donor ischemic time 184.3 ± 65.6 219.0 ± 52.4 .04
(min)
MHC mismatch 5.0 ± 0.8 5.0 ± 1.0 .9
Follow-up duration (d) 844 ± 506 825 ± 372 .3
BM, Bone marrow; MHC, major histocompatibility complex.
mycophenolate mofetil) were similar between the
study and control groups (Table II). 
Acute cellular rejection. The freedom from grade 3A
rejection at 6 months after transplantation was signifi-
cantly lower (P = .03) in control patients (40%) than in
those who received bone marrow (64%; Fig 2). The infu-
sion of donor bone marrow seems to have its impact
early after transplantation. During the first 6 months
after transplantation, the average number of episodes of
grade 3A rejection per patient was 1.4 ± 0.2 and 0.6 ±
0.2 in the control and study groups, respectively (P =
.02). However, this salutary effect disappears in the sub-
sequent follow-up, with the rates of 3A rejection
approaching 0.1 ± 0.1 and 0.2 ± 0.1 in the control and
study groups, respectively. Using the stepwise Cox pro-
portional hazard method to assess the influence of vari-
ous factors, which include age (donor and recipient),
sex, ischemic time, MHC matching, tacrolimus level,
and bone marrow infusion on acute rejection, we found
that donor bone marrow infusion is the only independent
prognostic factor that reduces acute rejection (P = .03;
risk ratio = 2.42; 95% confidence intervals = 1.08–5.41).
The Journal of Thoracic and
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Fig 1. Patient survival (Kaplan-Meier estimates) after heart transplantation between bone marrow and control
groups. BM, Bone marrow; CI, confidence interval.
Fig 2. Freedom from grade 3A rejection (Kaplan-Meier estimates) after heart transplantation between bone mar-
row and control groups. BM, Bone marrow; CI, confidence interval.
Allograft coronary artery disease. Allograft coro-
nary artery disease after transplantation was defined as
luminal irregularity and coronary stenosis seen on a
coronary angiogram or diffuse arteriopathy at autopsy.
In 34 patients in whom allograft coronary arteries
could be evaluated, the freedom from coronary artery
disease at 3 years after transplantation was 69% (con-
trol group, n = 13) and 78% (study group, n = 21) (P =
.9) (Fig 3). 
Donor cell chimerism. Detection of donor cell
chimerism was initially carried out by flow cytometric
technique, which can detect chimerism at a level of one
donor cell in 200 recipient cells (0.5%) and has been
shown to correlate well with the induction and mainte-
nance of tolerance in experimental models.12 In patients
whose levels of donor cells fall below this threshold,
molecular detection of donor human leukocyte antigens
by PCR (which could detect an equivalent of one donor
cell in 105 recipient cells) was performed. 
Flow cytometric analyses were feasible (when appro-
priate antibodies to disparate donor HLA antigens were
available) in 16 study patients and in 15 controls.
Overall, the level of donor chimerism was low (<3.0%)
(Figs 4 and 5). There was a marginal difference (P =
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Table II. Immunosuppression profiles of heart recipi-
ents with or without donor bone marrow infusion
Immunosuppression* BM + heart Heart alone P value
FK level (ng/mL) 12.7 ± 4.3 12.8 ± 4.4 .9
Prednisone dose (mg/d) 5.6 ± 5.8 8.3 ± 5.9 .07†
Patients on prednisone 17/28 (61%) 14/24 (58%) .9
Patients on a 3rd drug‡ 20/28 (71%) 14/24 (58%) .3
*Expressed as mean ± standard deviation, when appropriate.
†Mann-Whitney U test.
‡Either azathioprine or mycophenolate mofatil.
Fig 3. Freedom from allograft coronary artery disease (Kaplan-Meier estimates) between bone marrow and con-
trol groups. BM, Bone marrow; CI, confidence interval; CAD, coronary artery disease.
Fig 4. Levels of donor cell chimerism in recipients’ peripher-
al blood leukocytes. Donor cell chimerism was detected in
the peripheral blood leukocytes of heart recipients by flow
cytometry. Each circle represents one patient. Levels below
0.5% were considered not detectable. There was a marginal
difference (P = .08) in the overall levels of chimerism
between the study and control groups (analysis of variances
for repeated measures). However, chimerism persisted much
longer in the study group (P = .008). During the first 2
months after transplantation, the bone marrow group had a
higher proportion of patients with detectable chimerism.
Asterisk (*) indicates P < .05.
.08) in the overall levels of chimerism between the
study and control groups. However, the pattern of
chimerism development was significantly different
between the two groups (P = .008), with chimerism
persisting much longer in the study group. During the
first 2 months after transplantation, the bone marrow
group had a higher proportion of patients with
detectable chimerism. However, this difference did not
persist beyond 2 months after transplantation (Table
III). In both groups, the level of donor chimerism was
higher in the early postoperative period and decreased
with time. By 14 months after transplantation,
chimerism became virtually undetectable by flow
cytometry, suggesting that its levels had declined below
the threshold of detection for this technique (Fig 4). 
Due to a lack of appropriate primers for the MHC
class II in some donor-recipient pairs, detection of
chimerism by qualitative PCR was feasible in only 14
study and 13 control patients. The prevalence of donor
cell chimerism as determined by qualitative PCR on the
most recent blood sample was higher (13/14; 93%) in
the study group than in the control group (9/13; 69%),
but this difference did not reach statistical significance
(P = .2). In 2 study and 2 control female recipients
receiving male hearts, the levels of donor cell
chimerism were serially determined by nested PCR.9 As
was observed for recipients of other organs,9 the levels
of chimerism were at least 2 logs higher in the study
patients than in the control patients (data not shown). 
Immune modulation 
Mixed leukocyte reaction. Immune monitoring by
mixed leukocyte reaction was possible (only when
donor splenocytes were available) in 14 control and 16
study patients. Proliferative responses of recipients’
The Journal of Thoracic and
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Fig 5. Donor chimerism in the peripheral blood leukocytes of a heart recipient who received donor bone marrow
infusion. Recipient cells were stained with a primary mouse antibody against human MHC class I antigen, then
counterstained with fluorescein isothiocyanate (FITC) conjugated goat anti-mouse secondary antibody, and ana-
lyzed with an EPICS Elite flow cytometer (Coulter Corp, Hialeah, Fla). A, Before transplantation. B and C, One
and 6 months after transplantation. The number in the right lower quadrant indicates the percentage of donor cells.
PE, Phycoerythrin.
A B C
Table IV. Frequency of endomyocardial biopsy
growth in control and bone marrow recipients
Period after 
transplantation BM + heart Controls P value
0 to 6 mo 
No. of patients with 27 19
biopsy
Patients with no growth 8 (30%) 9 (47%) .22
6 to 12 mo
No. of patients with 19 14
biopsy
Patients with no growth 13 (68%) 6 (43%) .17
BM, Bone marrow.
Table III. Prevalence of donor chimerism* in peripheral
blood leukocytes of heart recipients
Time (mo) BM + heart Controls P value
0.5-2 11/13 (85%) 4/10 (40%) .006
3-5 5/9 (56%) 3/8 (38%) .6
6-8 7/12 (58%) 1/8 (13%) .07
9-11 6/8 (75%) 4/8 (50%) .4
12-14 4/9 (44%) 3/7 (43%) 1.0
15-20 2/9 (22%) 3/8 (38%) .6
BM, Bone marrow.
*By flow cytometry, chimerism is defined as having at least 0.5% of donor
cells.
peripheral blood leukocytes to donor splenocytes at
various times after transplantation were compared with
those obtained in pretransplantation samples. No dif-
ference in donor-specific immune modulation was dis-
cerned between the two groups for up to 1 year after
transplantation. Eighteen percent of patients in the
study group and 15% in the control group had donor-
specific hyporesponsiveness (data not shown). 
Lymphocyte growth assay. We have demonstrated
that a positive lymphocyte growth assay in endomyo-
cardial specimens that have low-grade rejection (grade
< 2) is highly predictive of subsequent high-grade
rejection (grade > 2).11 Therefore the lymphocyte
growth assay may be used as a surrogate marker of the
recipient’s immune reactivity toward the graft. The
absence of lymphocyte growth from the endomyocar-
dial specimens indicates less alloreactivity toward the
graft and vice versa. During the first 6 months after
transplantation, no difference was noted in the propor-
tion of patients with negative lymphocyte growth assay
(non-grower) between the study and control groups
(30% vs 47%, respectively; Table IV). In the subse-
quent 6 months (6-12 months after transplantation), the
proportion of non-growers was higher (although not to
a statistically significant degree) in the study group
than in the control group (68% vs 43%, respectively;
Table IV). This observation suggested a trend toward
less alloreactivity in recipients who had received con-
comitant bone marrow infusion. 
Discussion
The recognition that bone marrow chimerism is asso-
ciated with immunologic tolerance dates back more
than half a century. Billingham and associates13
observed that adult freemartin cattle (dizygotic twins
that share a common placenta during intrauterine life
and possess erythrocyte chimerism) permanently
accepted each other’s skin grafts. These investigators
were able to duplicate this observation in experimental
models by inoculating hematopoietic cells obtained
from MHC-disparate donors into fetal mice.14
Subsequently, chimerism with donor-specific tolerance
was achieved in adult animals by preconditioning the
host with total body irradiation,12 total lymphoid irradi-
ation,15 and the use of antilymphocyte globulin.16
Although clinical translation of tolerant models
requiring recipient conditioning with total lymphoid
radiation17 and total body radiation (Ildstad ST, person-
al communication, 2000) have been attempted, it is the
Monaco model,16 which used antilymphocyte globulin
induction therapy, that has been exploited extensively
in clinical transplantation. Monaco and associates18
were the first to apply this strategy to a renal recipient
in 1976. The first large-scale clinical trial in which the
Monaco model was used was carried out in cadaveric
renal recipients by Barber and colleagues.19 In this
study, graft survival was significantly better in the bone
marrow group than in the controls (90% vs 71% at 1
year). Other clinical evidence of benefits of bone mar-
row augmentation included a reduced need for
immunosuppression and a lower acute rejection rate. 
The rationale for the initiation of the current adjuvant
bone marrow infusion program was based on the dis-
covery by Starzl and coworkers1,2 that donor cells of
bone marrow lineages persisted at a low level in the
peripheral blood, lymphoid organs, and skin of long-
surviving kidney (n = 5; 10-29 years) and liver (n = 25;
3-22 years) recipients.1,2 On the basis of these observa-
tions, it was argued that the establishment of
microchimerism (the presence of a low level of donor
bone marrow–derived cell in solid organ recipients)
was perhaps essential for long-term allograft accep-
tance. It was therefore hypothesized that augmenting
this spontaneously occurring event with perioperative
donor bone marrow infusion may further enhance the
acceptance of the graft, especially of those organs that
are not endowed with a large quantity of passenger
leukocytes within their interstitium. To test this hypoth-
esis, in December 1992, we6 initiated a trial combining
donor bone marrow infusion with solid organ trans-
plantation, without recipient preconditioning. 
Following the lead at Pittsburgh, Garcia-Morales and
associates20 at the University of Miami have adopted a
modified protocol using multiple infusions of donor
bone marrow in renal transplant recipients. In this non-
randomized trial, 40 renal transplant recipients who
received unmodified donor bone marrow infusion were
compared with 100 contemporaneous control subjects.
All patients received induction therapy with OKT3 and
a maintenance immunosuppression regimen consisting
of tacrolimus and steroids; in some patients mycophe-
nolate mofetil was added as a third drug. Cryo-
preserved bone marrow cells were infused at two inter-
vals: between days 1 and 4 and between days 10 and 14
after transplantation. The bone marrow recipients had
higher levels of donor chimerism than control subjects,
both in their peripheral blood and in their bone marrow.
Notably, the levels of donor chimerism (especially
CD3+ and CD34+ cells) were 10-fold higher in the bone
marrow compartment than in the peripheral blood.
Patients receiving bone marrow also had more mitigat-
ed humoral and cellular immune responses than did the
control patients. Using the same induction and mainte-
nance immunosuppression protocol as employed by
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Garcia-Morales and associates,20 Ricordi and cowork-
ers21 have reported that liver allograft survival was sig-
nificantly higher in patients receiving multiple infu-
sions than in those receiving a single perioperative
infusion of donor bone marrow.
The intermediate-term results in heart recipients
reported herein confirm our preliminary data7 that the
infusion of unmodified donor bone marrow concurrent-
ly with heart transplantation is well tolerated and safe.
There was no evidence of graft-versus-host disease and
no complication that was related specifically to the
infusion of donor bone marrow. There was an increase
in the level of chimerism in the bone marrow recipients
as compared with the controls, a finding reminiscent of
that observed in the recipients of other organ allo-
grafts.9 Despite the similarity in the immunosuppres-
sion profiles, acute rejection was less prevalent in bone
marrow recipients than in the control patients.
Furthermore, there was a trend toward less alloreactiv-
ity toward the graft, as assessed by the lymphocyte
growth assay, in the study group. Although not statisti-
cally significant, the freedom from allograft coronary
artery disease at 3 years after transplantation was high-
er in bone marrow recipients (78% vs 69% in the con-
trols). It is conceivable that with a longer duration of
follow-up and a larger sample size, this difference may
approach statistical significance.
The mechanism that accounts for the lower rejection
rate in the bone marrow group remains to be elucidat-
ed. However, it is conceivable that donor bone marrow
cells may have down-regulated the recipient’s immune
system by suppressing the development of cytotoxic T
cells. In vitro studies by Mathew,22 Rachamin,23 and
their associates have demonstrated that human bone
marrow cells inhibited both the proliferative and cyto-
toxic responses in a dose-dependent manner. These in
vitro data supporting the existence of a veto mecha-
nism, which was originally described by Miller,24 have
been further corroborated by in vivo observations in
nonhuman primates25 and in human beings.26
Another possible mechanism by which the donor bone
marrow cells could have modulated the recipient’s
immune system is via clonal exhaustion of donor-reac-
tive cells. It is possible that the infused donor bone mar-
row cells, which can readily disseminate throughout the
recipient’s body, expose the recipient’s immune cells
with an excess of donor antigens, causing clonal activa-
tion followed by deletion of the donor-reactive T (and
possibly B) cells. This activation-induced tolerance,
which occurs exclusively in lymphoid organs or orga-
nized lymphoid collections, is analogous to the situation
in which all antigen-specific T cells are deleted when the
host is exposed to an excess load of that particular anti-
gen, such as a generalized infection with noncytopathic
viruses.27,28 This mechanism of tolerance is elegantly
described by Zinkernagel27 in the case of lymphocytic
choriomeningitis infection in mice. In the realm of trans-
plantation tolerance, the commonality between the toler-
ance to infectious agents and transplanted allografts has
been discussed in detail by Starzl and Zinkernagel.28
Of particular interest is the fact that even though
acute rejection is less prevalent in the bone marrow
group, there was no in vitro evidence of immune mod-
ulation in these patients as assessed by 1-way mixed
leukocyte reaction. The discrepancy between the in
vivo and in vitro responses as observed in this study is
not unique. This dichotomy between in vivo hypore-
sponsiveness (organ acceptance) and in vitro alloreac-
tivity, which has been referred to as “split toler-
ance,”29,30 further heightens the need for developing
more reliable in vitro techniques that would be more
predictive of graft tolerance.
In summary, the intermediate-term data from this cur-
rently ongoing clinical trial indicate that the infusion of
unmodified donor bone marrow concurrently with heart
transplantation is safe and is associated with an
increased level of donor cell chimerism. Furthermore,
the early immunologic events after cardiac transplanta-
tion appear to have been altered by the infusion of donor
bone marrow. When compared with the control patients,
bone marrow recipients had less acute rejection and less
alloreactivity (albeit not to a statistically significant
degree) by the lymphocyte growth assays. Although the
eventual salutary effect of donor-specific bone marrow
infusion in heart recipients remains speculative, it is
apparent that donor bone marrow infusion is feasible,
safe, and associated with less rejection. Inclusion of
concomitant infusion of donor bone marrow in future
strategies aiming to enhance the acceptance of cardiac
allografts must be seriously considered.
We thank Robert Duncan, PhD, Professor of Epidemiology
and Public Health, University of Miami, for his assistance
with statistical analyses.
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Discussion
Dr Verdi J. DiSesa (Chicago, Ill). Dr Pham and his col-
leagues have shown that unmodified donor bone marrow
administered intravenously shortly after heart transplantation
can reduce the incidence of moderate to severe rejection. This
is important since it represents a shift from a strategy of trans-
plant immune modulation based on nonspecific pharmacolog-
ic immune suppression to one whereby biologic manipulations
are used to induce donor-specific hyporesponsiveness. This is
Sir Peter Medawar’s actively acquired immune tolerance, and
I congratulate Dr Pham and his coauthors on an elegantly pre-
sented report of their attempts to produce it in patients. 
In heart transplantation, it is not the usual practice to per-
form prospective histocompatibility tissue antigen matching,
and the authors have not done so here. However, we and oth-
ers have shown that fortuitous MHC matching, identified ret-
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rospectively, can produce reductions in rejection similar to
those observed in this study. 
The authors have reported average MHC mismatching to
be the same in both groups, but have they looked at subsets of
patients within each group that may have had fortuitous
matching? Might this have played a role in the differences in
rejection that they saw? 
Transient chimerism in their study was also seen in patients
treated conventionally without bone marrow infusions. Why
did the authors not include a conditioning regimen, such as
irradiation, so as to enhance the degree and durability of bone
marrow engraftment? What is their explanation for the failure
to see a reduced proliferative response in the in vitro immune
assays? 
Finally, what do the authors think about the importance of
the nature of chimerism? Is it low level of all lineages of
donor hematopoietic cells that is important, or perhaps the
mere presence of any lineage of circulating donor cells? Does
it make any difference? 
Dr Pham. Thank you, Dr DiSesa, for your comments. To
answer your first question regarding a subset analysis of
patients with MHC match, the number of patients in our
study is too small to do that. Dr Joshua Miller’s group at the
University of Miami had identified a subset of renal recipi-
ents with DR match who received donor bone marrow infu-
sion. These recipients had better engraftment of the donor
cells than those without DR match. Furthermore, rejection
was less common in these recipients. Actually, 10 of 10
patients of that group had never had rejection. 
The second question is related to the conditioning of the
recipient: Why did we not give the recipient radiation or any
other cryoablative conditioning? The most robust means to
induce tolerance is the mixed chimerism achieved by radia-
tion that allows the engraftment of the stem cells of the bone
marrow. This type of tolerance had been reported initially by
Medawar and later by Suzanne Ildstad and David Sachs.
However, convincing the institutional review board to allow
us to use radiation initially was difficult. Furthermore, the
rationale of the current study is different from the classic
radiation chimera model. In this study we tried to enhance the
naturally occurring microchimerism. We do not know
whether donor bone marrow infusion will enhance graft
acceptance or not. A great body of experimental data suggests
that it would work. In the 1970s, Dr Monaco from Boston
showed that this form of treatment induced tolerance in the
small animal models. Subsequently, other groups have shown
the same results in the larger animal.
The discrepancy between the in vitro immune response ver-
sus the in vivo response (ie, graft acceptance) has been well
described in animal models. This phenomenon is called split
tolerance, where there is acceptance of the organ but no toler-
ance by in vitro (mixed lymphocyte reaction or cell-mediated
lymphocytotoxity) testing. It reflects the fact that a better or
more sensitive technique is needed to detect tolerance.
The stem cell is very important for the induction of toler-
ance because, if engrafted, it allows the propagation of donor
cells and donor antigens that allow clonal deletion of the
recipient lymphocytes. However, other mechanisms of toler-
ance such as clonal anergy and clonal exhaustion may also
play an important role in enhancing graft acceptance.
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